Skip to content

Alkermes ALKS Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
AbbVie logo
AbbVieABBV
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Arrowhead Research logo
Arrowhead ResearchARWR

Segments

By geography

See full
US$210.79M
IE$44.79M

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's deferred tax assets and other non-current assets?
Alkermes (ALKS) reported deferred tax assets and other non-current assets of $59.36M in Q1 2026.
How has Alkermes's deferred tax assets and other non-current assets changed year-over-year?
Alkermes's deferred tax assets and other non-current assets increased by 223.1% year-over-year, from $18.37M to $59.36M.
What is the long-term trend for Alkermes's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Alkermes's deferred tax assets and other non-current assets has grown at a 23.2% compound annual growth rate (CAGR), from $17.32M to $49.1M.